ArticlePDF AvailableLiterature Review

Depression in multiple sclerosis: A review



Several studies have reported high rates of depression in multiple sclerosis (MS) with a lifetime prevalence of approximately 50% and an annual prevalence of 20% not uncommon. Concern about the potential of new drug treatments to exacerbate or precipitate depression in MS has led to increased interest in the relation between MS and depression. This review on MS and depression identifies the following key issues: How common is depression in people with MS? Is depression in MS associated with lesions in specific regions of the central nervous system? Is there an increased risk of suicide in MS? Is there a higher than expected incidence of anxiety disorders in MS? Are fatigue and depressed mood related in MS? Is there a relation between depression and cognitive impairment in MS? Which psychosocial variables affect the development of depression in MS? Does treatment with interferon increase the risk of depression? How effective are treatments for MS patients with depression? Each of these issues is briefly reviewed with critical commentary, and some priorities for future research are suggested.
Depression in multiple sclerosis: a review
R J Siegert, D A Abernethy
J Neurol Neurosurg Psychiatry 2005;76:469–475. doi: 10.1136/jnnp.2004.054635
Several studies have reported high rates of depression in
multiple sclerosis (MS) with a lifetime prevalence of ,50%
and an annual prevalence of 20% not uncommon. Concern
about the potential of new drug treatments to exacerbate or
precipitate depression in MS has led to increased interest in
the relation between MS and depression. This review on
MS and depression identifies the following key issues: How
common is depression in people with MS? Is depression in
MS associated with lesions in specific regions of the central
nervous system? Is there an increased risk of suicide in MS?
Is there a higher than expected incidence of anxiety
disorders in MS? Are fatigue and depressed mood related
in MS? Is there a relation between depression and
cognitive impairment in MS? Which psychosocial variables
affect the development of depression in MS? Does
treatment with interferon increase the risk of depression?
How effective are treatments for MS patients with
depression? Each of these issues is briefly reviewed with
critical commentary, and some priorities for future research
are suggested.
See end of article for
authors’ affiliations
Correspondence to:
R J Siegert, Rehabilitation
Teaching and Research
Unit, Department of
Medicine, Wellington
School of Medicine,
University of Otago, PO
Box 7343, Wellington
South, New Zealand;
22 September 2004
In revised form
2 December 2004
13 December 2004
he presence of psychiatric symptoms in
multiple sclerosis (MS) has been known
since Charcot gave the first detailed clinico-
pathological description of ‘‘disseminated sclero-
sis’’ in his lectures at the Salpeˆtrie`re hospital in
the nineteenth century.
Among the psychiatric
symptoms noted by Charcot were pathological
laughing and weeping, euphoria, mania, hallu-
cinations, and depression. Indeed, Charcot’s
patient Mademoiselle V was described as experi-
encing a fit of lypemania (or severe depression),
along with hallucinations and paranoia.
However, it was not until the 1950s that
empirical research on the frequency of depres-
sion among people with MS really began.
addition to the neurological symptoms that
characterise MS, major depression is common,
with estimates of lifetime prevalence of major
depression in MS as high as 50%.
historically it has been difficult to disentangle
the direct effects of the disorder upon mood from
the non-specific effects of chronic illness, a
recent study suggests that the annual prevalence
of major depression in MS is elevated compared
with that in both healthy people and other
chronic conditions.
In that study, Patten et al
reported a 12 month prevalence rate of 25.7% for
major depression in people with MS in the 18–45
years age range. Of further concern is the finding
that suicidal ideation is relatively common
among people with MS, and that depression in
people with MS is often not detected and
Moreover, depression is an important
determinant of quality of life (QoL) in MS and
may well be the most important determining
Recently considerable interest has been
generated about the possible role of interferon
beta in precipitating depression in MS, and
although these concerns may not be warranted,
the issue of major depression in MS remains a
significant issue notwithstanding.
10 11
The aims
of the present review are to:
provide a brief overview of research on
depression in multiple sclerosis
highlight some of the issues emerging from
this research
suggest priorities for future research on this
Unipolar or major depression is a mental
disorder characterised by the presence of five of
the following symptoms for at least two weeks:
a sad mood for most of the day/most days
a loss of pleasure or interest in one’s usual
sleeping problems
psychomotor retardation or agitation
reduced appetite with weight loss (or the
a negative self-image
feelings of guilt and self-blame
reduced concentration and suicidal thinking.
The five symptoms must include sad, depressed
mood and/or loss of interest and pleasure in
usual activities.
A recent Australian study
reported a 12 month prevalence rate for major
depression in the community of 6.3%.
In a 1990
of affective disturbances in MS, Schiffer
noted that most studies had reported a higher
incidence and prevalence for depressive symp-
toms in MS compared with controls with a
different neurological illness. However, he also
commented that all these studies had design
weaknesses of varying degrees. In particular,
Schiffer noted that in most of these studies the
clinicians diagnosing depression were not blind
to the patient’s condition or to the hypotheses
at issue. He also noted problems relating to
Abbreviations: BDI, Beck Depression Inventory; CBT,
cognitive behavioural therapy; CES-D, Centre for
Epidemiological Studies’ Depression Scale; MS, multiple
sclerosis; SSRI, selective serotonin reuptake inhibitor
selection, diagnostic criteria and the vexed issue of the most
appropriate control group to compare MS patients with.
Notwithstanding these methodological issues, the finding of
a high rate of depression in MS seemed quite consistent.
Minden and colleagues examined 50 patients with MS
selected quasi-randomly from a patient register using a
structured psychiatric interview and standardised rating
scales for depression.
They reported that 54% of their
sample met the research diagnostic criteria (RDC) for major
depression at least once since their diagnosis whereas only
14% had met these criteria prior to it. Joffe et al assessed 100
consecutive patients attending an MS clinic in Canada using
the RDC for major depression and reported a lifetime
prevalence of 42%.
This figure did not include a proportion
of their sample that met the criteria for bipolar affective
disorder. In a study of 221 consecutive patients attending an
MS clinic in Vancouver, Sadovnick et al reported a lifetime
prevalence of 50% using a structured psychiatric interview.
They noted that this figure was considerably higher than the
rates of depression typically reported for samples with
chronic illness. Chwastiak et al undertook a mail survey of
1374 members of the Multiple Sclerosis Association in King
County, WA with 739 responses (a 54% response rate).
found that 42% of that sample had ‘‘clinically significant
depressive symptoms’’ according to the Centre for
Epidemiological Studies’ Depression Scale (CES-D) and 29%
scored in the moderate or severe range.
In a recent study, Patten et al used data from the Canadian
Community Health Survey (CCHS) to provide a population
based perspective on major depression and MS.
The point
here is that previous studies mostly relied upon patients
attending MS clinics, or on current health centre registers,
and consequently could have overestimated the prevalence of
depression. Patten and colleagues examined a sample of
115 071 participants, aged 18 or older, from the CCHS and
found 322 with MS. The 12 month prevalence of depression
was 25.7% compared with 8.9% for people without MS.
In summary, studies have repeatedly reported that the
prevalence of depression in MS is high even when compared
with other groups with a chronic illness. For example,
lifetime prevalence rates of 40–50% and 12 month prevalence
rates around 20% have been typically reported for samples
taken from patients attending MS clinics. However, a number
of methodological issues suggest caution in interpreting these
figures. Most of the prevalence studies have taken samples
from patients attending an MS clinic, and those patients
coping well in the community might be underrepresented.
Another issue concerns the wide variety of measures used to
diagnose and quantify the severity of depression. There seems
little or no consensus among researchers as to the clinical
‘‘gold standard’’ for diagnosing depression in patients with
MS. Added to this is the risk with MS that the somatic
symptoms, such as fatigue, may lead to inflated estimates of
depression. This is perhaps most likely when behavioural
rating scales that were designed for use in a general
psychiatric setting are relied upon. Consequently, it might
be prudent to use those screening measures validated in
populations of patients with chronic illness.
It also
behoves us to remember that many of the issues involved
in screening for depression among patients with MS, such as
missing the diagnosis or failing to treat the depression, are
also important issues in primary health care and not unique
to the neuropsychiatry of MS.
The question as to whether or not depression in MS is
associated with lesions in specific areas of the central nervous
system has generated considerable interest recently. This
question has particular relevance for understanding and
treating depression in patients with MS. It may also be
important for developing a clearer understanding of the
complex relation that exists between biological and psycho-
social factors in the genesis of depression.
In one of the
earlier studies of this nature Rabins et al examined the
computed tomography (CT) scans of 37 patients who were
part of a larger sample of 102 patients with MS in whom
psychiatric symptoms were studied longitudinally.
observed that MS patients with brain lesions were more
depressed than those patients with lesions only in the spinal
cord and also that depression was positively correlated with
the extent of neurological impairment. However, the 37
patients whose scans were compared, were those for whom a
CT scan had already been completed prior to the study or
where one was requested during the study as part of their
ongoing medical care. Hence they may not be fully
representative of the larger group of 102 patients in that
study or of patients with MS in general.
Honer et al used magnetic resonance imaging (MRI) to
compare eight MS patients with psychiatric disorders with
eight matched control MS patients and concluded that these
disorders were associated with temporal lobe lesions.
However, this rather small sample comprised a mixed group
of psychiatric diagnoses and it is not clear how specific that
conclusion might be with regard to depression. A study by
Ron and Logsdail compared rate of psychiatric morbidity in a
sample of 116 MS patients with a control group with physical
They reported a significantly higher frequency
of psychiatric ‘caseness’ in the MS group. The focus of this
study was not on depression per se but rather on psychiatric
illness in general. However, the authors did note that
flattened affect (and also delusions and thought disorder)
was associated with greater pathology in the temporal-
parietal region. Pujol et al examined 45 consecutive out-
patients at an MS clinic in Barcelona and looked for a relation
between scores on the Beck Depression Inventory (BDI) and
lesion location and volume.
Although no relation was found
between total lesion volume and depression, they did find
that BDI scores were significantly associated with lesions in
the arcuate fasciculus of the left hemisphere. This relation
accounted for 17% of the total variance in BDI scores.
However, it should be noted that only seven of the patients
had scores in the moderate to severe range according to the
BDI (that is, .17). Thus it is uncertain quite what the
implications of their results might be for patients with MS
diagnosed as having major depression.
Zorzon and colleagues reported an MRI study of 95
consecutive patients with definite MS at a clinic in Trieste.
They used the Hamilton Rating Scales for Depression and
Anxiety and a psychiatric interview by a clinician who was
blind to the hypotheses. Of their 95 patients 18 (19%) met the
criteria for major depression. The regional brain volumes and
lesion loads of the depressed and non-depressed patients
were compared. The authors reported that severity of
depression and a diagnosis of major depression were
correlated with right frontal lesion load and with right
temporal brain volume. They also noted that severity of
depressive symptoms correlated significantly with total
temporal volume as well as right hemisphere volume.
However, although statistically significant, these correlations
were all modest and in the range 0.20–0.30.
The most recent imaging study of MS and depression, and
arguably the strongest in methodological terms, was reported
by Feinstein and colleagues, who used brain MRI to compare
21 MS patients with major depression with 19 carefully
matched non-depressed MS patients.
A feature of this study
was that the depressed patients all met the DSM-IV criteria
for major depression as assessed by a structured psychiatric
interview. In addition, the authors screened over a thousand
470 Siegert, Abernethy
consecutive patients at an MS clinic according to rigorous
exclusion criteria. For example, any patient with a premorbid
history of psychiatric disorder, including depression, was
excluded. The major finding from this study was that the
depressed MS patients had ‘‘more hyperintense lesions in the
left inferior medial frontal regions and greater atrophy of left
anterior temporal regions’’.
Together, these two brain
regions accounted for ,42% of the variance in a logistic
regression model for predicting depression.
In summary, imaging studies to date vary widely in both
their design and rigour and there are few if any unequivocal
conclusions that can be made. However, on balance the
evidence seems to favour an association between depression
in MS with greater neuropathology in the left anterior
temporal/parietal regions. There is a need for further research
on this question. Perhaps what is most lacking thus far is any
clear theoretical model of the neuropathology of depression
and how precisely this relates to MS. Given recent advances
in our understanding of the neuropathology, neuropsychol-
ogy and neuroimaging of depression, this may soon occur.
The high prevalence rates for depression in MS raise the
question as to whether or not patients with MS might then be
at elevated risk of suicide. Sadovnick and colleagues analysed
the causes of death in a large sample of patients at two
Canadian MS clinics, one in Ontario and one in British
The combined sample from both clinics com-
prised ,3126 patients and a total of 145 deaths occurred in
the time period 1972–88. The cause of death was able to be
clearly established from records for 119 patients of whom 56
died as a direct result of complications of MS. Out of the
remaining 63 patients whose deaths were not as a result of
MS complications, 18 (28.6%) died by suicide. A further two
patients whose deaths came under the category of ‘‘mis-
cellaneous causes’’ were suspected suicides. The authors
concluded that the proportion of suicides as a cause of death
was 7.5 times that for the age-matched general population.
The authors noted that earlier studies had not reported such
high rates of suicide in MS samples. In addition, one might
expect higher rates of distress in a sample of clinic attendees.
A Danish study employed the Danish Multiple Sclerosis
Registry and the Danish National Register of Cause of Death
to examine the prevalence of suicide among people with
The authors were able to examine data covering ,5525
cases for whom the onset of MS occurred between 1953
and1985. They reported a total of 53 suicides over this period
and noted that the expected number of suicides in a group of
this size (adjusting for age and so forth) would be 28. They
noted that the risk was highest among the younger, male
patients. In a recent study, Feinstein examined a sample of
140 consecutive patients attending an MS clinic in Canada
using standardised measures to detect suicidal ideation and
He reported a lifetime prevalence for suicidal intent
of 28.6% (40 participants) and nine (6.4%) had actually
attempted suicide. Feinstein examined those variables that
predicted suicidal intent using logistic regression and found
that living alone, severe depression and alcohol problems
together accounted for ‘‘an 85% predictive accuracy for
suicidal intent’’. Of particular concern in that study were
that two thirds of those patients with ‘‘current major
depression’’ were not receiving antidepressants and a third
of suicidal patients had not received any psychological
The high rate of comorbidity among anxiety and mood
disorders might suggest that anxiety disorders will also be
common in people with MS. Whereas the existing literature
tends to support this notion the amount of rigorous
epidemiological evidence seems limited compared with that
for depression. For example, in a recent review of research on
the assessment of emotional problems in people with MS,
only five of the 15 cited studies had included a standardised
measure of anxiety.
However, those studies that have
specifically assessed anxiety have typically reported quite
high rates. For example, Smith and Young assessed the
prevalence of both anxiety and depression in a sample of 88
consecutive patients attending an MS clinic, using the BDI
and the Hospital Anxiety and Depression Scale (HADS).
They reported that 34% scored as ‘‘cases’’ for anxiety on the
HADS with 22 patients (25%) needing treatment for it. In a
study where the focus was on the neural correlates of
depression and anxiety in MS, Zorzon et al assessed ‘‘95
consecutive unselected patients with clinically definite MS’’
in Trieste.
They reported a median anxiety score on the
HADS of 18 (the usual cut-off for highly probable cases is 10/
11). Janssens and colleagues surveyed 101 newly diagnosed
patients and their partners and found high rates of anxiety in
both the patients (34%) and their partners (40%).
Thus several recent studies have reported high levels of
anxiety in people with MS. However, these studies have all
employed samples taken from patients attending clinics who
might well have higher levels of symptoms than a commu-
nity based sample of people with MS. Moreover, even among
the patients attending clinics there is no detailed information
regarding the specific subtypes of anxiety disorder present.
One puzzling aspect of MS for clinicians and researchers alike
is the nature of the relation between depression and fatigue
in MS. Fatigue is a common symptom in both depression and
MS. Mohr et al note that ‘‘A relationship between fatigue and
depression has long been suspected in MS’’, but ‘‘While
depression and fatigue are often assumed to be related in MS,
why or how this relationship might exist has remained
generally unarticulated’’.
They also note two studies in
which medication that has been effective for fatigue in MS
has not shown any concomitant impact upon depression. It
appears that earlier studies examining fatigue and depression
in MS actually found little evidence for a close link between
the two. For example, Krupp et al compared 32 consecutive
patients attending an MS clinic in New York with healthy
controls matched by age and sex.
Although 47% of the MS
patients had scores suggesting clinical depression on the
CES-D, they found no significant correlation with fatigue as
measured by a visual analogue scale. Nor was fatigue
correlated with neurological disability as measured by the
Expanded Disability Status Scale (EDSS). However, fatigue
was a common and distressing symptom among the MS
group and the authors’ conclusion emphasised the impor-
tance of viewing fatigue as a discrete symptom of MS that is
not accounted for by depression. A subsequent study by this
group also reported no correlation between depression and
fatigue in patients with either MS or systemic lupus
Similarly, a study in the Netherlands by
Vercoulen et al observed that fatigue was a common and
troubling symptom in patients with MS but found no
correlation with depression (BDI) or disability (EDSS).
contrast with these earlier studies more recent research has
tended to report a relationship between depression and
One of the first studies to report a statistically significant
correlation between depression and fatigue in people with
MS was an investigation of psychosocial correlates of fatigue
in 139 American patients with MS. However, the correlations
were low, with fatigue severity and depression correlating at
only 0.17.
A stronger association was noted by Ford et al
MS and depression 471
who examined fatigue and depression in 78 consecutive
patients attending an MS clinic and claimed to be the ‘‘first
reported study to demonstrate a significant correlation
between fatigue and mood level’’.
Although that claim
might be debatable in the light of the aforementioned study,
a notable feature of Ford’s study was that it conceptualised
fatigue as multidimensional with separate scores for mental,
physical, and total fatigue. Depression was more strongly
related to mental fatigue (r = 0.54, p,0.0001) than physical
(r = 0.31, p,0.01). Subsequent research has mostly tended to
confirm the relation between fatigue and depression but has
also highlighted its complexity—emphasising the multi-
dimensional nature of fatigue and the influence of moderat-
ing variables such as helplessness and recreational activity.
One longitudinal study found that the relation was dynamic
as ‘‘relationships of fatigue with physical and mental health
change during the course of a year’’.
Another found that
depression and fatigue were independent predictors of QoL
in MS.
Although fatigue is well recognised as a somatic symptom
accompanying depression and anxiety, prolonged fatigue is
also common in community based studies of psychological
Moreover it appears that some people who
appear to have no other explanation experience fatigue as the
main feature of a psychological illness.
13 46
For this reason
some psychiatrists interested in the epidemiology and
classification of psychological illness have recommended
the recognition of neurasthenia to account for this group of
patients and to analyse the value of treatments.
Whether or
not fatigue results directly from brain lesions in MS or as a
psychological reaction to the illness in a predisposed person
remains uncertain. However, there is increasing acknowl-
edgement that fatigue in MS is multidimensional and that
both mental and physical fatigue need to be assessed.
41 42 48
Treating depression in MS patients does seem to produce
improvements in self-reports of fatigue. However, the
evidence to date is based upon one uncontrolled study of
patients who received either cognitive behaviour therapy
(CBT) or supportive group therapy or sertraline.
approach would not be expected to be as effective in those
patients without any symptoms of depression. The serotonin
selective reuptake inhibitors (SSRIs) have been shown not to
be useful in the treatment of chronic fatigue syndrome,
reversible inhibitors of monoamine oxidase inhibitor-A
(RIMAs) are helpful in treating some aspects of fatigue
syndromes, and CBT is beneficial.
39 49–51
Whether a CBT
approach is also as useful in MS is unknown at present.
There is a substantial body of evidence that impaired
cognitive functioning is common in MS with prevalence
rates in community samples typically around 40% or
For example, a British study of 200 people selected
quasi-randomly from an MS register, reported cognitive
impairment in 46% with memory problems in 34% and
executive problems in 33%.
In contrast with the confusing
picture about depression and lesion location noted above Rao
has observed that ‘‘The degree and pattern of cognitive
dysfunction is highly correlated with the amount and
location of white-matter disease within the cerebral hemi-
Cognitive impairment is also now well documen-
ted in depression, although this may only be the case for
depression in older and middle aged patients with a history of
severe depression.
Consequently, it is important to under-
stand the nature of the relation, if any, between cognitive
impairment and depression in MS.
As with fatigue, most of the earlier studies reported no
clear relation between cognitive dysfunction and depression
in MS whereas more recent research has tended to report a
positive correlation. For example, in his 1986 review of the
neuropsychology of MS, Rao noted that: ‘‘Euphoria, apathy,
lack of interest, and irritability are frequently noted to occur
in patients with widespread cerebral involvement, while
depression, postulated to be of a reactive type, is more
commonly seen in patients without cognitive dysfunction or
with only mild involvement’’.
Similarly, in 1995 he observed
that ‘‘Recent studies have suggested that measures of
cognitive dysfunction and depression are not correlated
suggesting that depression is not a causative factor in the
development of cognitive dysfunction’’.
The same conclu-
sion was reached by Brassington and Marsh in a more recent
review of the neuropsychology of MS.
In that paper they
summarised 10 studies that addressed this issue and
concluded thus: ‘‘Numerous studies have reported no
association between cognitive impairment and depression
in patients with MS’’.
This lack of any association between depression and
cognitive impairment in MS seems rather surprising given
the mounting evidence for the neuropsychological deficits
that can accompany depression.
30 56 59
If physically healthy
people with depression are prone to cognitive dysfunction it
seems paradoxical that this is not the case for people with MS
who are depressed. However, a recent programme of research
by Peter Arnett and colleagues may shed some light on this
seeming paradox.
Arnett has suggested that it is effortful
rather than automatic information processing that is most
likely to be compromised in depressed MS patients. Hence
performance may be quite normal on routine tasks but
impaired on those tasks that place demand upon attentional
resources—such as speeded tests of information processing,
working memory and complex tests of executive function-
Additional support for a link comes from the work of
Demaree and DeLuca.
These authors have criticised some
of the earlier studies for relying upon correlation analyses
and using neuropsychological measures that are not sensitive
to the cognitive effects of depression. They note that the
relation between depression and cognitive impairment is best
established for severe depression and primarily in relation to
information processing speed and working memory. Arnett
and colleagues have also reported that cognitive impairments
in patients with MS seem to be closely correlated with mood
and negative self-evaluations but less so with the vegetative
symptoms of depression.
In summary, earlier research studies consistently failed to
find any clear relation between depression and cognitive
impairment in MS. However, some recent work suggests that
information processing speed, working memory and execu-
tive functioning may indeed be affected in cases where the
depression is in the moderate to severe range. Whether or not
these impairments are reversible upon treating the depres-
sion remains unknown.
A growing body of research attests to the importance of
psychosocial factors in determining whether or not a person
with MS develops depression.
The variables that have
attracted the most attention are coping style and social
support. The research findings on coping with MS closely
resemble those in the broader literature on coping with
stress—that is, positive adjustment is typically associated
with problem focused coping and higher symptom levels are
associated with emotion focused coping or escape avoid-
However, it is our impression that some methodolo-
gical and theoretical advances in research on coping have yet
to be fully used in the research on coping in MS. For example,
Folkman has suggested that narrative research methods can
supplement standardised checklists to determine ways of
coping that are not tapped by such measures.
This might be
472 Siegert, Abernethy
important when considering coping in people dealing with
one specific illness such as MS.
Social support is also associated with better adjustment
although the relation is clearly not a simple linear one. For
example, Pakenham examined the stress and coping model
of illness in people with MS and found that social support
had a beneficial effect on adjustment but only under
circumstances of high perceived threat.
Uccelli and collea-
gues found that participating in a peer support group for MS
patients had little consistent positive effect upon mood and
may have actually been a negative influence on those
participants who were coping well at the outset of the
A recent study by Mohr and colleagues has suggested
that treating depression actually results in improvements on
a number of aspects of social support. Such findings are not
as perplexing as might first seem and there is evidence that
depression may actually cause reduced social support.
again, we suspect that clarification of the complex relation
between depression and social support in people with MS,
will be achieved by closer integration with the broader
literature on stress, coping, and social support. Other
psychosocial variables that might affect mood in MS include
illness intrusiveness, uncertainty, hope, and spirituality.
With the advent of interferon beta as a treatment for
relapsing remitting MS in the early 1990s concern arose
regarding the potential for this drug to cause or exacerbate
The initial concern apparently sprang from
reports of a suicide and four attempted suicides that occurred
among the treated group in the first clinical trial.
A more
recent case report may have added to this concern with the
authors claiming that the case ‘‘suggests a causal link
between interferon beta-1a treatment of MS and major
depressive disorder’’.
However, with the high prevalence
rates for depression in MS noted above, it is difficult to draw
any meaningful conclusions from anecdotal accounts or
individual case reports. As this issue was comprehensively
reviewed by Feinstein in 2000, we will limit our discussion to
studies published since that review. In that review Feinstein
concluded that ‘‘Given the many methodological pitfalls
inherent in all studies to date, it is premature to conclude
that disease modifying drugs are associated with depres-
However, data from the Controlled High-Risk
Subjects Avonex Multiple Sclerosis Prevention Study
(CHAMPS) study was published soon after, in which a
significantly higher rate of depression (20%) was reported
among the 193 patients treated with interferon than among
the 190 controls who received only a placebo (13%).
Notwithstanding that finding most recent studies have
found little in the way of firm evidence that interferon
treatment is likely to result in depression among people with
For example, the Prevention of Relapses and
Disability by Interferon beta-1a Subcutaneously in Multiple
Sclerosis (PRISMS) clinical trial included ,560 participants
with relapsing remitting MS from 22 centres across nine
countries randomly allocated to two treatment arms or a
placebo control group and used three standardised measures
of depressive symptoms. The authors concluded that pre-
treatment depressed mood was the best predictor of
subsequent depressive symptoms but found no differences
in reported levels of depression across the three groups.
Moreover, the finding that the best predictor of depression in
MS patients treated with interferon is a previous history of
depressed mood has been consistently reported elsewhere.
83 84
A subsequent study by this group also concluded that
‘‘depression is not a side effect of interferon B1a’’ when used
to treat patients with secondary progressive MS.
Patten and
colleagues have also reported that rates of depression are the
same for patients treated with interferon as for patients
treated with glatiramer acetate in clinical settings.
is also accumulating from other research groups that the
concerns about interferon treatment and depression may
have been undue.
Perhaps the important message here for
clinicians is that screening for depression and monitoring of
mood should be a feature of the medical management of all
patients with MS—regardless of whether or not they are
receiving interferon.
There is a small but growing literature on the treatment of
depression in patients with MS. Schiffer and colleagues
reported the first and only double blind, controlled trial of
antidepressants in the treatment of depression in people with
In that study they found that tricyclics (desipramine)
were more effective than a placebo while noting that some
patients had problems with anticholinergic side effects which
limited their dosage. Interestingly, significant improvements
were observed according to clinical judgement and the
Hamilton Rating Scale for Depression but not on the BDI.
There is also some evidence from open label trials that SSRIs
and the monoamine oxidase inhibitor moclobemide can be
effective treatments. Feinstein cautions that SSRIs may have
impaired sexual functioning as a side effect and this is a
particular concern given that it is also a common symptom of
Mohr and Goodkin found five studies that they considered
rigorous enough for inclusion in a meta-analysis.
concluded that depressed MS patients responded well to
treatment with either psychotherapy or antidepressants
(desipramine) but noted that psychotherapy with an
emphasis on coping skills was more likely to be effective
than insight oriented therapy. The results of their meta-
analysis also suggested that if left untreated depression in
people with MS was likely to worsen. Interestingly, these
authors also speculate that depression in MS might be
particularly responsive to treatment, arguing that most MS
patients lack any extensive history of depression and rarely
have comorbid psychiatric diagnoses. The same laboratory
has since reported that both CBT and sertraline (an SSRI)
were effective in the treatment of depression in MS patients
compared to supportive-expressive group therapy.
In summary, there is a small body of controlled studies
indicating that depression in people with MS responds well
to two treatments—psychotherapy that emphasises the
development of active coping skills (such as CBT) and
antidepressant medication. In cases where a patient with MS
fails to respond to SSRIs, Feinstein advises clinicians to
consult the general psychiatric literature.
Depression is common in MS with annual prevalence rates as
high as 20% reported and lifetime prevalence rates of 50% not
uncommon. There is some evidence that depression in MS is
associated with greater neuropathology in the left anterior
temporal/parietal region although the evidence for a close
association between depression and lesion locality is not
strong. There is some evidence that MS patients may have an
increased risk of suicide and this is probably most true for
younger male patients and those patients who are socially
isolated, severely depressed and have alcohol problems.
Anxiety disorders also seem more prevalent in MS although
the research here is both less extensive and less rigorous than
for depression and it is largely reliant upon data from
samples attending MS clinics. Earlier research on fatigue and
depression in MS consistently found no obvious relation
although recent studies have tended to report a correlation.
At the same time, these recent studies have also suggested
MS and depression 473
that the relation is a complex, dynamic one and that fatigue
is best conceptualised as multidimensional. Early studies also
found little evidence for a relation between depression and
cognitive impairment. However, recent studies suggest that
cognitive impairment is likely to be exacerbated when
depression is in the moderate to severe range. The initial
concern about interferon treatment causing depression in
patients with MS seems unwarranted in the light of several
recent studies addressing this issue. While all of these issues
merit further research the outstanding question continues to
be why depression among people with MS is not routinely
screened. Moreover, given the evidence for its responsiveness
to treatment why is it that depression in people with MS is so
infrequently treated?
Authors’ affiliations
R J Siegert, D A Abernethy, Department of Medicine, Wellington School
of Medicine and Health Sciences, University of Otago, Wellington, New
Competing interests: D Abernethy has acted as an unpaid consultant to
Schering NZ the manufacturers of Interferon B-1b (Betaferon)
1 Charcot JM. Lectures on the diseases of the nervous system. Philadelphia:
Henry C Lea, 1879.
2 Butler MA, Bennett TL. In search of a conceptualization of multiple sclerosis: a
historical perspective. Neuropsychol Rev 2003;13:93–111.
3 Schiffer RB. Disturbances of affect. In: Rao SM, ed. Neurobehavioral aspects
of multiple sclerosis. New York: Oxford University Press, 1990.
4 Feinstein A. The neuropsychiatry of multiple sclerosis. Can J Psychiatry
5 Patten SB, Beck CA, Williams JVA, et al. Major depression in multiple
sclerosis: a population-based perspective. Neurology 2003;61:1524–7.
6 Feinstein A. An examination of suicidal intent in patients with multiple
sclerosis. Neurology 2002;59:674–8.
7 Janardhan V , Bakshi R. Quality of life in patients with multiple sclerosis: the
impact of fatigue and depression. J Neurol Sci 2002;205:51–8.
8 Janssens ACJW, van Doorn PA, de Boer JB, et al. Impact of recently
diagnosed multiple sclerosis on quality of life, anxiety, depression and distress
of patients and partners. Acta Neurol Scand 2003;108:389–95.
9 Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in
multiple sclerosis patients: disability, depressive mood, fatigue and sleep
quality. Acta Neurol Scand, 2004;110:6–13.
10 Feinstein A. Multiple sclerosis, disease modifying treatments and depression:
a critical methodological review. Mult Scler 2000;6:343–8.
11 Patten SB, Fridhandler S, Beck CA, et al. Depressive symptoms in a treated
multiple sclerosis cohort. Mult Scler 2003;9:616–20.
12 American Psychiatric Association. Diagnostic and statistical manual of mental
disorders - DSM-IV-TR. Arlington, VA: American Psychiatric Publishing, Inc,
13 Andrews G, Henderson S, Hall W. Prevalence, comorbidity, disability and
service utilisation: Overview of the Australian National Mental Health Survey.
Br J Psychiatry 2001;178:145–53.
14 Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp
Psychiatry 1987;9:426–34.
15 Joffe RT, Lippert GP, Gray TA, et al. Mood disorder and multiple sclerosis.
Arch Neurol 1987;44:376–8.
16 Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis.
Neurology 1996;46:628–32.
17 Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity
of illness in multiple sclerosis: epidemiologic study of a large community
sample. Am J Psychiatry 2002;159:1862–8.
18 Benedict RHB, Fishman I, McClellan MM, et al. Validity of the Beck Depression
Inventory—Fast Screen in multiple sclerosis. Mult Scler 2003;9:393–6.
19 Avasarala JR, Cross AH, Trinkaus K. Comparative assessment of Yale Single
Question and Beck Depression Inventory Scale in screening for depression in
multiple sclerosis. Mult Scler 2003;9:307–10.
20 Aikens JE, Reinecke MA, Pliskin NH, et al. Assessing depressive symptoms in
multiple sclerosis: Is it necessary to omit items from the original Beck
Depression Inventory? J Behav Med 1999;22:127–42.
21 McAlpine DD, Wilson AR. Screening for depression in primary care: What do
we still need to know? Depress Anxiety 2004;19:137–45.
22 Shelton RC, Hollon SD, Purdon SE, et al. Biological and psychological aspects
of depression. Behav Ther 1991;22:201–28.
23 Rabins PV, Brooks BR, O’Donell P, et al. Structural brain correlates of
emotional disorder in multiple sclerosis. Brain 1986;109:585–97.
24 Honer WG, Hurwitz T, Li DKB, et al. Temporal lobe involvement in multiple
sclerosis patients with psychiatric disorders. Arch Neurol 1987;44:187–90.
25 Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and
MRI study. Psychol Med 1989;19:887–95.
26 Pujol J, Bello J, Deus J, et al. Lesions in the left arcuate fasciculus region and
depressive symptoms in multiple sclerosis. Neurology 1997;49:1105–10.
27 Zorzon M, de Masi R, Nasuelli D, et al. Depression and anxiety in multiple
sclerosis. A clinical and MRI study in 95 subjects. J Neurol 2001;248:416–21.
28 Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple
sclerosis patients with major depression. Neurology 2004;62:586–90.
29 Harrison PJ. The neuropathology of primary mood disorder. Brain
30 Shenal BV, Harrison DW, Demaree HA. The neuropsychology of depression:
a literature review and preliminary model. Neuropsychol Rev
31 Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry
32 Sadovnick AD, Eisen K, Ebers GC, et al. Cause of death in patients attending
multiple sclerosis clinics. Neurology 1991;41:1193–6.
33 Stenager EN, Stenager E, Koch-Henricksen N, et al. Suicide and multiple
sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry
34 Nicholl CR, Lincoln NB, Francis VM, et al. Assessment of emotional problems
in people with multiple scleros is. Clin Rehabil 2001;15:657–68.
35 Smith SJ, Young CA. The role of affect on the perception of disability in
multiple sclerosis. Clin Rehabil 2000;14:50–4.
36 Mohr DC , Hart SL, Goldberg A. Effects of treatment for depression on fatigue
in multiple sclerosis. Psychosom Med 2003;65:542–7.
37 Krupp LB, Alvarez LA, LaRocca NG, et al. Fatigue in multiple sclerosis. Arch
Neurol 1988;45:435–7.
38 Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale:
application to patients with mult iple sclerosis and systemic lupus
erythematosus. Arch Neurol 1989;46:1121–3.
39 Vercoulen JHMM, Hommes OR, Swanink CMA, et al. The measurement of
fatigue in patients with multiple sclerosis: a multidimensional comparison with
patients with chronic fatigue syndrome and healthy subjects. Arch Clin Neurol
40 Schwartz CE, Coulthard-Morris L, Qi Zeng MS. Psychosocial correlates of
fatigue in multiple sclerosis. Arch Phys Med Rehabil 1996;77:165–70.
41 Ford H, Trigwell P, Johnson M. The nature of fatigue in multiple sclerosis.
J Psychosom Res 1998;45:33–8.
42 Schreurs KMG, de Ridder DTD, Bensing JM. Fatigue in multiple sclerosis:
reciprocal relationships with physical disabilities and depression. J Psychosom
Res 2002;53:775–81.
43 Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its
relationship to depression and neurologic disability. Mult Scler
44 van der Werf SP, Evers A, Jongen PJH, et al. The role of helplessness as
mediator between neurological disability, emotional instability, experienced
fatigue and depression in patients with multiple sclerosis. Mult Scler
45 Voss WD, Arnett PA, Higgison CIJRJ, et al. Contributing factors to depressed
mood in multiple sclerosis. Arch Clin Neurol 2002;17:103–15.
46 Hickie IB, Hooker AW, Hadzi-Pavlovic D, et al. Fatigue in selected primary
care settings: sociodemographic and psychiatric correlates. Med J Aust
47 Hickie I, Hadzi-Pavlovic D, Ricci C. Reviving the diagnosis of neurasthenia.
Psychol Med 1997;27:989–94.
48 Schwid SR, Covington MMSB, Goodman AD. Fatigue in multiple sclerosis:
Current understanding and future directions. J Rehabil Res Dev
49 Hickie IB, Wilson AJ, Wright JM, et al. A randomized, double-blind placebo-
controlled trial of moclobemide in patients with chronic fatigue syndrome.
J Clin Psychiatry 2000;61:643–8.
50 Ridsdale L, Darbishire L, Seed PT. Is graded exercise better than cognitive
behaviour therapy for fatigue? A UK randomized trial in primary care.
Psychol Med 2004;34:37–49.
51 Deale A, Chalder T, Marks I, et al. Cognitive behavior therapy for chronic
fatigue syndrome: a randomized controlled trial. Am J Psychiatry
52 Rao SM, Leo GJ, Bernardin L, et al. Cognitive dysfunction in multiple sclerosis.
I. Frequency, patterns, and prediction. Neurology 1991;41:685–91.
53 Rao SM, Leo GJ, Ellington L, et al. Cognitive dysfunction in multiple-sclerosis.
2. Impact on employment and social functioning. Neurology 1991; 41:692–6.
54 McIntosh-Michaelis SA, Roberts MH, Wilkinson SM, et al. The prevalence of
cognitive impairment in a community survey of multiple sclerosis. Br J Clin
Psychol 1991; 30:333–48.
55 Rao SM. Neuropsychology of multiple sclerosis. Curr Opin Neurol
56 Elliott R. The neuropsychological profile in unipolar depression. Trends Cogn
Sci 1998;2:447–54.
57 Rao SM. Neuropsychology of multiple sclerosis: a critical review. J Clin Exp
Neuropsychol 1986;8:503–42.
58 Brassington JC, Marsh NV. Neuropsychological aspects of multiple sclerosis.
Neuropsychol Rev 1998;8:43–77.
59 Hartlage S, Alloy LB, Vazquez C, et al. Automatic and effortful processing in
depression. Psychol Bull 1993;113:247–78.
60 Arnett PA, Higginson CI, Voss WD, et al. Depressed mood in multiple
sclerosis: relationship to capacity-demanding memory and attentional
functioning. Neuropsychology 1999;13:434–46.
61 Arnett PA, Higginson CI, Voss WD, et al. Depression in multiple sclerosis:
relationship to working memory capacity. Neuropsychology
62 Arnett PA, Higginson CI, Randolph JJ. Depression in multiple sclerosis:
relationship to planning ability. J Int Neuropsychol Soc 2001;7:665–74.
474 Siegert, Abernethy
63 Landro NI, Celius EGHS. Depressive symptoms account for deficient
information processing speed but not for impaired working memory in early
phase multiple sclerosis (MS). J Neurol Sci 2004;217:211–16.
64 Demaree HA, Gaudino E, DeLuca J. The relationship between depressive
symptoms and cognitive dysfunction in multiple sclerosis. Cogn
Neuropsychiatry 2003;8:161–71.
65 Demaree HA, DeLuca J, Gaudino E, et al. Speed of information processing as
a key deficit in multiple sclerosis. J Neurol Neurosurg Psychiatry
66 DeLuca J, Gaudino EA, Diamond BJ, et al. Acquisition and storage deficits in
multiple sclerosis. J Clin Exp Neuropsychol 1998;20:376–90.
67 Pakenham KI. Adjustment to multiple sclerosis: application of a stress and
coping model. Health Psychol 1999; 18:383–92.
68 McCabe MP, McKern S, McDonald E. Coping and psychological adjustment
among people with multiple sclerosis. J Psychosom Res 2004;56:355–61.
69 Williams RM, Turner AP, Hatzakis M, et al. Social support among veterans
with multiple sclerosis. Rehabil Psychol 2004;49:106–13.
70 Folkman S, Moskowitz JT. Coping : pitfalls and promise. Annu Rev Psychol
71 Uccelli MM, Mohr LM, Battaglia MA, et al. Peer support groups in multiple
sclerosis: current effectiveness and future directions. Mult Scler
72 Mohr DC, Classen C, Barrera JM. The relationship between social support,
depression and treatment for depression in people with multiple sclerosis.
Psychol Med 2004;34:533–41.
73 Devins GM, Schnek ZM. Multiple sclerosis. In: Frank RG, Elliott TR, eds.
Handbook of Rehabilitation Psychology. Washington DC: American
Psychological Association, 2000.
74 Mullins LL, Cote MP, Fuemmeler BF, et al. Illness intrusiveness, uncertainty,
and distress in individuals with multiple sclerosis. Rehabil Psychol
75 Lynch SG, Kroencke DC, Denney DR. The relationship between disability and
depression in multiple sclerosis: the role of uncertainty, coping and hope. Mult
Scler 2001;7:411–16.
76 McNulty K, Livneh H, Wilson LM. Perceived uncertainty, spiritual well-being
and psychosocial adaptation in individuals with multiple sclerosis. Rehabil
Psychol 2004; 49:91–9.
77 Klapper MD. Letter to the editor [letter]. Neurology 1994;44:188.
78 Pandya R, Patten S. Depression in multiple sclerosis associated with interferon
beta-1a (Rebif). Can J Psychiatry 2002;47:686.
79 Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon Beta-1a
therapy initiated during a first demyelinating event in multiple sclerosis.
N Engl J Med 2000;343:898–904.
80 Patten SB, Metz LM. Interferon B-1a and depression in relapsing-remitting
multiple sclerosis: an analysis of depression data from the PRISMS clinical
trial. Mult Scler 2001;7:243–8.
81 Patten SB, Metz LM. Interferon B1a and depression in secondary progressive
MS: Data from the SPECTRIMS Trial. Neurology 2002;69:744–6.
82 Zephir H, De Seze J, Stojkovic T, et al. Multiple sclerosis and depression: an
influence of interferon B therapy. Mult Scler 2003;9:284–8.
83 Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b
and depression: a prospective investigation. J Neurol 2002;249:815–20.
84 Mohr DC, Likosky W, Dwyer P, et al. Course of depression during the initiation
of interferon beta-1a treatment for multiple sclerosis. Arch Neurol
85 Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression
associated with multiple sclerosis. Am J Psychiatry 1990;147:1493–7.
86 Mohr DC, Goodkin DE. Treatment of depression in multiple sclerosis. Clin
Psychol Sci Pract 1999;6:1–9.
87 Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for
individual cognitive-behavior therapy, supportive-expressive group
psychotherapy, and sertraline for the treatment of depression in multiple
sclerosis. J Consult Clin Psychol 2001;69:942–9.
MS and depression 475
... In support of this, Jiang et al. identified increased MOG and MAG serum levels, indicating demyelination, in depressive patients . While typical demyelinating diseases such as multiple sclerosis present with different symptoms than MDD, these diseases show a strong association with depression, as reviewed by Siegert and Abernethy (2005). A possible overlap in the pathomechanism of multiple sclerosis and depression is therefore likely. ...
Full-text available
Background Numerous cortical and subcortical structures have been studied extensively concerning alterations of their integrity as well as their neurotransmitters in depression. However, connections between these structures have received considerably less attention. Objective This systematic review presents results from recent neuroimaging as well as neuropathologic studies conducted on humans and other mammals. It aims to provide evidence for impaired white matter integrity in individuals expressing a depressive phenotype. Methods A systematic database search in accordance with the PRISMA guidelines was conducted to identify imaging and postmortem studies conducted on humans with a diagnosis of major depressive disorder, as well as on rodents and primates subjected to an animal model of depression. Results Alterations are especially apparent in frontal gyri, as well as in structures establishing interhemispheric connectivity between frontal regions. Translational neuropathological findings point to alterations in oligodendrocyte density and morphology, as well as to alterations in the expression of genes related to myelin synthesis. An important role of early life adversities in the development of depressive symptoms and white matter alterations across species is thereby revealed. Data indicating that stress can interfere with physiological myelination patterns is presented. Altered myelination is most notably present in regions that are subject to maturation during the developmental stage of exposure to adversities. Conclusion Translational studies point to replicable alterations in white matter integrity in subjects suffering from depression across multiple species. Impaired white matter integrity is apparent in imaging as well as neuropathological studies. Future studies should focus on determining to what extent influencing white matter integrity is able to improve symptoms of depression in animals as well as humans.
... MS often manifests in young adults between the ages of 20 and 50 (Baum and Rothschild, 1981;Hammond, 2000), is more common in women (2:1 ratio; Taylor et al. 2010) and the incidence in Tasmania is ~7 times higher than it is in the Northern Territory (McLeod et al., 1994;Palmer et al., 2013b), which is consistent with the observation that the incidence of MS increases with increasing distance from the equator (Simpson et al., 2011). People with MS can experience a variety of symptoms, which include vision loss and vertigo (Regan et al., 1977;Frohman et al., 2005), eye and back pain (Moulin et al., 1988;Filippo et al., 2016), fatigue (Braley and Chervin, 2010), impaired coordination (Broekmans et al., 2013;Sbardella et al., 2013) and memory loss (Chiaravalloti and DeLuca, 2008), which can be accompanied by comorbid depression (Chwastiak et al., 2002;Siegert and Abernethy, 2005) and anxiety (Korostil and Feinstein, 2007). MS symptoms can be unpredictable and are highly dependent on the severity and location of demyelinated lesions in the central nervous system (CNS; (Popescu et al., 2013). ...
Full-text available
Throughout life, oligodendrocyte progenitor cells (OPCs) proliferate and differentiate into new myelinating oligodendrocytes. As OPCs express ionotropic glutamate receptors and voltage-gated channels, they are able to detect and respond to neuronal activity. In this context, N-Methyl-D-aspartic acid (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor bind glutamate and alters the behaviour of cells of the oligodendrocyte lineage, however, the requirement of kainate receptors and voltage-gated calcium channels (VGCC) remains unclear. In Chapter 1 of this thesis, I review the regulatory the role of ion channels and ionotropic receptors in oligodendrogenesis. In Chapter 2, I characterise the expression of VGCCs by adult OPCs and demonstrate their capacity to influence adult OPC survival. In Chapter 3, I explore the importance of kainate receptor for OPC generation and myelination and examine their role within the central nervous system (CNS). In Chapter 4, I outline my research findings and describe how this research has informed my research goals and understanding of the relationship between neuronal activity and myelination. Research findings: In Chapter 2, I conditionally deleted Cacna1c, a gene encoding the VGCC CaV1.2, from OPCs in the adult mouse brain. Tamoxifen was delivered to P60 Cacna1cfl/fl (control) and Pdgfrα-CreER :: Cacna1cfl/fl (CaV1.2-deleted) mice and whole cell patch clamp recordings revealed that CaV1.2 deletion reduced L-type voltage-gated calcium entry into adult OPCs by ~60%. The conditional deletion of CaV1.2 from adult OPCs significantly increased their proliferation but did not affect the number of new oligodendrocytes produced or influence the length or number of internodes they elaborated. Unexpectedly, CaV1.2 deletion resulted in the dramatic loss of OPCs from the corpus callosum, such that 7 days after tamoxifen administration CaV1.2-deleted mice had an OPC density ~42% that of control mice. However, OPC density recovered within 2 weeks of CaV1.2 deletion, as the lost OPCs were replaced by surviving CaV1.2-deleted OPCs. As OPC density was not affected in the motor cortex or spinal cord, I have concluded that calcium entry through CaV1.2 is a critical survival signal for a subpopulation of callosal OPCs, but not for all OPCs, in the mature CNS. In Chapter 3, I show that Grik4 mRNA is highly expressed by cells throughout the adult mouse brain, and the loss of this gene (Grik4 knockout mice; Grik4 −/−) reduces anxiety- and depressive-like behaviour and progressively impair motor function. Such phenotypes can be produced by demyelination, however, OPC and oligodendrocyte numbers are normal in Grik4 -/- mice. While myelination is also normal in Grik4−/− mice, and callosal compound action potentials (CAP) travel at normal velocity, their amplitude is reduced. However, subtle axonal abnormalities were detected and layer 5 pyramidal neurons in the primary motor cortex received significantly fewer synaptic inputs. Therefore, Gluk4-containing kainate receptors are critical for motor circuit maintenance and consequently motor function in adult mice.
... Lifetime prevalence of depression is at least three times higher in RRMS patients than in general population [3,4], and mood disorders have been associated with risk of clinical relapses [5]. Moreover, besides the disease is characterized by increased physical disability over time [6], some symptoms, such as fatigue and cognitive impairment, are also commonly associated with depression [7][8][9]. ...
Full-text available
Background Mood disorders have been associated with risk of clinical relapses in multiple sclerosis (MS), a demyelinating disease mediated by myelin-specific T cells. Objectives We aimed to investigate the impact of major depressive disorder (MDD) and cytokine profile of T-cells in relapsing remitting MS patients. Methods For our study, plasma and PBMC were obtained from 60 MS patients (30 with lifetime MDD) in remission phase. The PBMC cultures were stimulated with anti-CD3/anti-CD28 beads or myelin basic protein (MBP), and effector and regulatory T cell phenotypes were determined by flow cytometry. The cytokine levels, both in the plasma or in the supernatants collected from PBMC cultures, were quantified by Luminex. In some experiments, the effect of serotonin (5-HT) was investigated. Results Here, higher Th17-related cytokine levels in response to anti-CD3/anti-CD28 and MBP were quantified in the plasma and PBMC cultures of the MS/MDD group in comparison with MS patients. Further, elevated frequency of CD4⁺ and CD8⁺ T cells capable of producing IL-17, IL-22 and GM-CSF was observed in depressed patients. Interestingly, the percentage of myelin-specific IFN-γ⁺IL-17⁺ and IFN-γ⁺GM-CSF⁺ CD4⁺ T cells directly correlated with neurological disabilities. In contrast, the occurrence of MDD reduced the proportion of MBP-specific CD39⁺Tregs subsets. Notably, the severity of both neurological disorder and depressive symptoms inversely correlated with these Tregs. Finally, the addition of 5-HT downregulated the release of Th17-related cytokines in response to anti-CD3/anti-CD28 and myelin antigen. Conclusions In summary, our findings suggested that recurrent major depression, by favoring imbalances of effector Th17 and Treg cell subsets, contributes to MS severity.
Full-text available
The purpose of this thesis study was to assess short term memory, working memory and executive functions of Relapsing Remitting Multiple Sclerosis (RRMS) patients. The sample consisted of 25 RRMS patients from Ankara Ufuk Univesity Department of Neurology, Turkish MS Association Branch of Ankara and 25 healthy participants. The groups were matched in terms of age, gender, level of education and hand dominance. Information Sheet were used for sociodemographic characteristics, such as health and physiological status, Beck Depression Inventory were used for depression level, State-Trait Anxiety Inventory were used for anxiety level, Visual Aural Digit Span Test B Form, Wisconsin Card Sorting Test, Backward Digit Span Task, Stroop Test T-BAG Form, Wechsler Memory Scale: Revised Form Visual Memory Subtest, and Trail Making Test were used for cognitive functions. Results showed that there was no significant difference between RRMS patients and healthy controls in terms of verbal short-term memory capacity, phological loop capacity, perseveration, inhibition and set shifting skills. However, RRMS patients performed significantly worse than healthy controls in visuo-spatial short term memory capacity, visuo-spatial skecth pad capacity and conceptualization skills. In addition, age, mood (depression and anxiety), the duration of disease, the number of relapses, and the duration from the last relapse were found to be negatively correlated with short-term and working memory, executive function performance of RRMS patients. The results of this current study indicated that RRMS patients’ short-term and working memory, executive functions were impaired. Also, these cognitive impairments were associated with RRMS patients’ age, mood, the duration of disease, the number of relapses, and the duration from the last relapse.
Full-text available
Die Rehabilitation von Gangstörungen bei Patienten mit MS und Schlaganfall erfolgt häufig mithilfe eines konventionellen Laufbandtrainings. Einige Studien haben bereits gezeigt, dass durch eine Erweiterung dieses Trainings um eine virtuelle Realität die Motivation der Patienten gesteigert und die Therapieergebnisse verbessert werden können. In der vorliegenden Studie wurde eine immersive VR-Anwendung (unter Verwendung eines HMD) für die Gangrehabilitation von Patienten evaluiert. Hierbei wurden ihre Anwendbarkeit und Akzeptanz geprüft sowie ihre Kurzzeiteffekte mit einer semi-immersiven Präsentation (unter Verwendung eines Monitors) und mit einem konventionellen Laufbandtraining ohne VR verglichen. Der Fokus lag insbesondere auf der Untersuchung der Anwendbarkeit beider Systeme und der Auswirkungen auf die Laufgeschwindigkeit und Motivation der Benutzer. Im Rahmen einer Studie mit Innersubjekt-Design nahmen zunächst 36 gesunde Teilnehmer und anschließend 14 Patienten mit MS oder Schlaganfall an drei experimentellen Bedingungen (VR über HMD, VR über Monitor, Laufbandtraining ohne VR) teil. Sowohl in der Studie mit gesunden Teilnehmern als auch in der Patientenstudie zeigte sich in der HMD-Bedingung eine höhere Laufgeschwindigkeit als beim Laufbandtraining ohne VR und in der Monitor-Bedingung. Die gesunden Studienteilnehmer berichteten über eine höhere Motivation nach der HMD-Bedingung als nach den anderen Bedingungen. Es traten in beiden Gruppen keine Nebenwirkungen im Sinne einer Simulator Sickness auf und es wurden auch keine Erhöhungen der Herzfrequenzen nach den VR-Bedingungen detektiert. Die Bewertungen des Präsenzerlebens waren in beiden Gruppen in der HMD-Bedingung höher als in der Monitor-Bedingung. Beide VR-Bedingungen erhielten hohe Bewertungen für die Benutzerfreundlichkeit. Die meisten der gesunden Teilnehmer (89 %) und Patienten (71 %) präferierten das HMD-basierte Laufbandtraining unter den drei Trainingsformen und die meisten Patienten könnten sich vorstellen, es häufiger zu nutzen. Mit der vorliegenden Studie wurde eine strukturierte Evaluation der Anwendbarkeit eines immersiven VR-Systems für die Gangrehabilitation geprüft und dieses erstmals in den direkten Vergleich zu einem semi-immersiven System und einem konventionellen Training ohne VR gesetzt. Die Studie bestätigte die Praktikabilität der Kombination eines Laufbandtrainings mit immersiver VR. Aufgrund ihrer hohen Benutzerfreundlichkeit und der geringen Nebenwirkungen scheint diese Trainingsform besonders für Patienten geeignet zu sein, um deren Trainingsmotivation und Trainingserfolge, wie z. B. die Laufgeschwindigkeit, zu steigern. Da immersive VR-Systeme allerdings nach wie vor spezifische technische Installationsprozeduren erfordern, sollte für die spezifische klinische Anwendung eine Kosten-Nutzen-Bewertung erfolgen.
Background: The coronavirus disease 2019 (COVID-19) pandemic has broad negative impact on physical and mental health of people with chronic neurological disorders such as multiple sclerosis (MS). Objective: We present a machine learning approach leveraging passive sensor data from smartphones and fitness trackers of people with MS to predict their health outcomes in a natural experiment during a state-mandated "stay-at-home" period due to a global pandemic. Methods: First, we extract features that capture behavioral changes due to the "stay-at-home" order. Then, we adapt and apply an existing algorithm to these behavioral change features to predict the presence of depression, high global MS symptom burden, severe fatigue, and poor sleep quality during the "stay-at-home" period. Results: Using data collected between November 2019 and May 2020, algorithm detects depression with an accuracy of 82.5% (65% improvement over baseline; f1-score: 0.84), high global MS symptom burden with an accuracy of 90% (39% improvement over baseline; f1-score: 0.93), severe fatigue with an accuracy of 75.5% (22% improvement over baseline; f1-score: 0.80), and poor sleep quality with an accuracy of 84% (28% improvement over baseline; f1-score: 0.84). Conclusions: Our approach could help clinicians better triage patients with MS and potentially other chronic neurological disorders for interventions and aid patient self-monitoring in their own environment, particularly during extraordinarily stressful circumstances such as pandemics that would cause drastic behavioral changes. Clinicaltrial: Not Applicable.
Little research has studied the relationship between self‐concept, psychiatric symptoms and quality of life on Multiple Sclerosis (MS). We assessed the impact of disease perception (expectation and knowledge) on this metrics according to time from diagnosis. Observational, cross‐sectional, multicentre study. Group 1 included patients with up to 3 months from MS diagnosis whereas Group 2 included patients with MS diagnosis established for more than 12 months and less than 36 months. A 19‐item true/false questionnaire developed by the investigators to assess disease perception, HADS, FSS and EQ‐5D‐3L questionnaires were used. 90 patients from six centres were included (38 in Group 1). 80% had a good disease knowledge whereas only 48% reported positive expectations. There were no differences in disease knowledge, disease expectations, HADS, FSS and EQ‐5D. We found an inverse correlation between disease knowledge and problems in self‐care (p=0.018) and fatigue (p=0.032). Patients with worst expectations about the disease were more anxious (p=0.012 on HADS and p<0.001 on EQ‐5D). They also reported more problems in mobility (p=0.002), self‐care (p=0.005), usual activities (p=0.009) and pain (p=0.001) and a worst health status comparing with the last 12 months (p<0.001) and with the best imaginable status (p<0.001). Our study showed no association between disease duration and disease perception. Patients with less disease knowledge reported more problems in self‐care and higher fatigue scores. Patients with worst disease expectations were more anxious and reported a worst health status. More attention should be driven to perceived health status in MS patients.
Background : Higher levels of total physical activity (PA) are associated with better health-related quality of life (HRQOL) in individuals with multiple sclerosis (MS). The benefits of PA across the activity continuum have not been well-studied. The goal of this study was to compare the associations between total PA, strenuous PA, moderate PA, and mild PA and HRQOL in a large cohort of individuals with MS using both generic and neurologic disease-specific questionnaires. Longitudinal changes in PA and HRQOL over two years were also examined Methods : Subjects enrolled in SysteMS completed the Godin Leisure Time Exercise Questionnaire (GLTEQ) to measure PA. Subjects also completed generic (SF-36) and neurologic disease-specific (NeuroQoL) HRQOL measures. GLTEQ and HRQOL measures were administered at baseline and 24 months. The associations between the GLTEQ total leisure activity (TLA), strenuous PA, moderate PA and mild PA and scores on NeuroQoL and SF-36 were estimated using Spearman's correlation coefficient and partial Spearman's correlation coefficient adjusting for age, sex and Expanded Disability Status Scale (EDSS) measured by a provider. To further investigate the associations between mild PA and HRQOL measures, the associations between mild PA and HRQOL were estimated in participants who reported no moderate or strenuous PA in the last week. The changes in GLTEQ TLA scores and each component score were compared to the changes in NeuroQoL and SF-36 over 24 months using Spearman's correlation coefficient and partial Spearman's correlation coefficient adjusting for age, sex and EDSS. Results : Statistically significant weak correlations were observed between GLTEQ TLA and NeuroQoL and SF-36 domains, with higher levels of TLA being associated with better HRQOL outcomes. After adjusting for age, sex and EDSS, all correlations were attenuated. Strenuous and moderate levels of PA were similarly associated with many HRQOL outcomes, but mild PA was only weakly correlated with NeuroQoL Lower Extremity Function. There was limited change in PA over 24 months. In a subgroup of participants who reported mild PA, but no moderate or strenuous PA, there were no significant associations with NeuroQoL or SF-36 domains at baseline, but increases in mild PA over two years were moderately associated with improvement on NeuroQoL Upper Extremity Function and SF-36 Mental Health and Mental Component Summary. Conclusion : There were weak associations between TLA and HRQOL across a wide range of HRQOL variables. In addition, both strenuous PA and moderate PA were weakly associated with many HRQOL outcomes, but mild PA was only associated with lower extremity function. Increases in mild PA in a subgroup of individuals who reported no strenuous or moderate PA at baseline were associated with improvements in HRQOL at 24 months. These findings suggest that programs aimed at increasing PA across the activity continuum may lead to improvements in multiple areas of HRQOL in individuals with MS.
Full-text available
The third ventricle width (3VW) is an easily calculated measure of brain atrophy. The aim of this study was to evaluate the relation of 3VW to cognitive impairment with adjustment for demographic and clinical confounders, including depression, anxiety, and fatigue, as well as to disability in patients with multiple sclerosis (MS). Symbol Digit Modalities Test, California Verbal Learning Test, Brief Visuospatial Memory Test-Revised, Expanded Disability Status Scale (EDSS), Hospital Anxiety and Depression Scale, and Modified Fatigue Impact Scale (MFIS) were analysed in 93 patients with MS. Neuropsychological performance was compared to that of 150 healthy controls. Axial images from 3D FLAIR were used to measure 3VW. In total, 25% of MS patients were impaired in at least two neuropsychological tests. Cognitive impairment and EDSS were associated with 3VW. Age and 3VW were the strongest predictors of cognitive impairment. The multiple regression model including age, 3VW, education, EDSS, and MFIS explained 63% of the variance of neuropsychological tests results, whereas 3VW, age and duration of the disease were significant predictors of EDSS. This study confirms the predictive value of 3VW for neurological status of patients with MS, especially for cognitive impairment after adjustment for demographic and clinical confounders.
Full-text available
It was in the mid-nineties when a senior colleague of mine, Dr. Bojan Biocina, introduced me to something called “OpenHeart-L” on The Heart Surgery Forum website. Suddenly, a whole new world appeared in front of me! The possibility to communicate with colleagues from all around the globe was amazing. And not only that—one could ask anything, and there was always someone who had an answer, gave a piece of advice…what to do, what to was magic! The person responsible for this whole idea of sharing information and interactive communication was Mark Levinson. At that time I was more a lurker than a poster, eagerly waiting for discussions to develop and learning from other people’s posts.
Objective This study was concerned with examining the coping and psychological adjustment of people with multiple sclerosis (MS) and determining how they were different in these dimensions from people from the general population. The role of severity and duration of illness as well as levels of social support on coping style and adjustment were also evaluated. Method The participants were 381 (144 men, 237 women) people with MS and 291 (101 men, 190 women) people from the general population. Results The results demonstrated that people with MS (particularly men) were less likely to adopt coping styles related to problem solving and seeking support and demonstrated poorer levels of adjustment on all dimensions. Adopting a wishful thinking coping style, as well as a lack of problem-focused coping or failure to seek social support, was also more likely to be associated with poorer psychological adjustment for both men and women with MS. Levels of health impairment were only minimally related to psychological adjustment, particularly for men. Discussion These findings highlight the importance of developing educational programs that include strategies to adopt more problem-focused coping strategies, so that people with MS can more readily adjust to their illness.<br /
Contrary to expectation the use of surgery in multiple sclerosis is an extensive topic, but many of the surgical options available are ‘last resort’ measures — few offer real value in terms of alteration of a patient’s way of life.
This study examined the use of a stress and coping model of adjustment to multiple sclerosis (MS). A total of 122 MS patients were interviewed and completed self-administered scales at Time 1 and 12 months later, Time 2 (n = 96). Predictors included stressful life events, illness (duration, severity, and disability), social support, appraisal (threat and control/challenge), and coping (problem focused and emotion [wishful thinking, self-blame, and avoidance] focused). Adjustment outcomes were Time 2 depression, global distress, social adjustment, and subjective health status. Results from hierarchical regression analyses indicated that after controlling for the effects of Time-1 adjustment, better Time-2 adjustment was related to less disability, greater reliance on problem-focused coping, and less reliance on emotion-focused coping. There was limited support for the stress buffering effects of coping and social support. Findings offer some support for the use of a stress and coping model of adaptation to MS.
The aim of this article is to review the results of outcome studies of the treatment of depression in patients with multiple sclerosis (MS) using meta-analysis. All treatments for depression in MS were found to be significantly more effective than no treatment. Patients in control groups that received no treatment, as opposed to minimal treatment, tended to become more depressed over time, suggesting that untreated depression worsens without treatment. There appears to be no significant difference in efficacy between psychotherapy and antidepressant medication. Psychotherapies that focus on improving coping skills are more effective at reducing depression than psychotherapies that focus on increasing insight. We conclude that patients with MS should be evaluated routinely for depression. Patients reporting symptoms of depression should be referred for treatment since active intervention is effective at reducing depression and untreated symptoms are likely to worsen.
Depression is a suspected side effect of multiple sclerosis (MS) treatment with interferon β-1a. However, this has not been confirmed by rigorous studies. Several psychological symptom rating scales were completed during the PRISMS clinical trial of subcutaneous interferon β-1a (Rebif®) for relapsing - remitting MS. We conducted an analysis of these data in order to determine whether symptom elevations were associated with treatment. The PRISMS clinical trial included 560 subjects from 22 centres in nine countries. There were two active treatment arms (44 mcg × 3 and 22 mcg × 3 subcutaneously three times per week) and a placebo group. Two hundred and sixty-seven of these subjects were enrolled at English speaking study centres, where psychiatric symptom ratings were obtained at baseline, 6, 12, 18 and 24 months using the Center for Epidemiological Studies Depression Rating Scale (CES-D), the General Health Questionnaire (GHQ) and the Beck Hopelessness Scale (BHS). After randomization, the groups completing these scales were similar in terms of age, gender, EDSS, duration of illness and employment status. Median CES-D scores in the high dose, low dose and placebo groups at baseline were also similar: 8.0, 7.0 and 8.0, respectively. After 6 months of treatment, the median change in CES-D score was zero in all three groups. The proportion of subjects exceeding the traditional CES-D cut-point for clinically significant depression (>15) after 6 months of treatment was strongly associated with pre-treatment depression (RR 2.9, 95% C.I.: 1.8 - 4.7), but not with treatment group (chi-square=1.64, d.f.=2, P=0.44). The results were comparable at 12, 18 and 24 months and when ratings from the other scales were evaluated. This analysis confirms that depression is common in persons with MS: the incidence of CES-D depression in the first 6 months of follow-up was 15.6%. However, no evidence of increased depressive symptomatology was observed in association with interferon b-1a (Rebif®).